Summary: Indication by the Board of Directors and Executive Management of
Pharmexa about participation in Pharmexa's rights issue.
Pharmexa has learnt that the members of the Board of Directors and Executive
Management of Pharmexa who hold shares in Pharmexa have made a decision to
exercise their preemptive rights and subscribe for new shares in Pharmexa's
recently announced rights issue.
The Board of Directors and Executive Management hold a combined 0.23% of the
shares of Pharmexa as of today.
Hørsholm, January 21, 2008
Jakob Schmidt
CEO
Additional information:
Jakob Schmidt, CEO, tel +45 4516 2525
Claude Mikkelsen, Vice President, Corporate Affairs and Communication, tel +45
4516 2525 or +45 4060 2558
For the editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer and serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer,
arthritis, bone degeneration and Alzheimer's disease, as well as infectious
diseases such as HIV, influenza, hepatitis and malaria. Company programs
include GV1001, a peptide vaccine that has entered Phase III trials in
pancreatic cancer and Phase II trials in liver cancer, and a number of HIV and
hepatitis vaccines in Phase I/II. Collaborative agreements include H. Lundbeck,
Innogenetics, IDM Pharma and Bavarian Nordic. With operations in Denmark,
Norway and USA, Pharmexa employs approximately 105 employees and is listed on
the OMX Nordic Stock Exchange Copenhagen under the trading symbol PHARMX.
